Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb
Catalogue Number: 12-9156-ABO
12-9156 Image
12-9156 Image
12-9156 Image
Figure 1: Flow cytometry analysis with 1 µg/mL Anti-IL17A (secukinumab biosimilar) mAb (12-9156) on Expi293 cells transfected with Human IL17A protein (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram).
12-9156 Image
Figure 2: Coomassie Staining of SDS Page gel loaded with 5ug Anti-IL17A (consentyx) (secukinumab biosimilar) mAB.
| Manufacturer: | Abeomics |
| Type: | Recombinant Monoclonal |
| Alias: | CTLA-8,CTLA8,IL-17,IL-17A,IL17 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug, 50 mg |
| Host name: | Human |
| Clone: | |
| Isotype: | IgG1 |
| Immunogen: | |
| Application: | FACS |
Description
Description: Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis, moderate to severe plaque psoriasis. Biologics are medicines that are human-made through genetic engineering techniques and closely related to a protein that occurs naturally in the body. Secukinumab blocks an inflammatory protein called IL-17, thus improving joint pain and swelling from arthritis and rash from psoriasis. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Additional Text
Purification
Affinity Purified
Antibody Clonality
Monoclonal
Application Notes
FACS 1:100
12-9156 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations